In osteosarcoma, Remodelin inhibits osteosarcoma cell growth, and by conducting a structure-based virtual screen of a specific chemical library and FDA-approved drugs in a drug bank, researchers have shown that paliperidone and AG-401 can bind to NAT10 and inhibit osteosarcoma cell growth in vivo and in patient-derived xenograft (PDX) models; however, treatment with paliperidone and AG-401 does not alter NAT10 expression, in contrast to the effect seen with Remodelin [97]. The gene discussed is NAT10; the disease is osteosarcoma.